Format

Send to

Choose Destination
Cell Res. 2017 Jan;27(1):74-95. doi: 10.1038/cr.2016.157. Epub 2016 Dec 27.

Dendritic cell-based immunotherapy.

Author information

1
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.

Abstract

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.

PMID:
28025976
PMCID:
PMC5223236
DOI:
10.1038/cr.2016.157
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center